Nursing Pharmacology Practice Questions: Chapter 33-34 Protein Tyrosine Kinase Inhibitors of VEGFR: sunitinib (Sutent)

Nursing Cancer Chemotherapy Pharmacology Practice Questions: Chapter 33-34 Protein Tyrosine Kinase Inhibitors of VEGFR: sunitinib (Sutent)

VEGF receptors:
1. Receptors for vascular endothelial growth factor (VEGF).
2. Involved in vasculogenesis
3. Involved in angiogenesis
4. A & B
5. B & C
6. A & C
7. A, B & C
Formation of the circulatory system is described by the term angiogenesis.
1. True
2. False
VEGFR, protein, exhibits tyrosine kinase activity.
1. True
2. False
Sunitinib exhibits:
1. Antitumor activity
2. Antiangiogenic activity
3. Both
4. Neither
Sunitinib inhibits:
1. Platelet-derived growth factors
2. Vascular endothelial growth factors (e.g. VEGFR1 etc.)
3. Colony-stimulating factor type 1
4. A & B
5. B & C
6. A & C
7. A, B & C
Sunitinib Is described by:
1. Small-molecule
2. Orally bioavailable
3. Multiple kinase inhibition including VEGFR2
4. Multiple kinase inhibition including VEGFR2
5. A & B
6. B & C
7. B & C
8. A, B & C
Sunitinib (Sutent) metabolism:
1. Primarily excreted unchanged in the urine
2. Primarily metabolized by the cytochrome P450 isoform CYP3A4
3. Primarily metabolized by phase II glucuronidation
4. B & C
Therapeutic use/uses of sunitinib:
1. Metastatic renal cell cancer
2. Pancreatic NET (pancreatic neuroendocrine tumor)
3. Both
4. Neither
Primary adverse effects/effects associated with sunitinib administration are common to antiangiogenic inhibitors. Side effects include bleeding, proteinuria, hypertension and intestinal perforation. The multitargeted characteristic of this tyrosine kinase inhibitor results in extended adverse effect presentations compared to bevacizumab.
1. True
2. False
Since sunitinib may cause harm to the fetus if administered to a pregnant woman, effective contraception should be used during therapy and for least a month following the last sunitinib dose. This conclusion is not surprising given that sunitinib inhibits angiogenesis, clearly important in normal fetal development.
1. True
2. False